U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C53H72N2O12
Molecular Weight 929.147
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of CISATRACURIUM

SMILES

C[N@@+]1(CCc2cc(c(cc2[C@@]1([H])Cc3ccc(c(c3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@@+]4(C)CCc5cc(c(cc5[C@@]4([H])Cc6ccc(c(c6)OC)OC)OC)OC

InChI

InChIKey=YXSLJKQTIDHPOT-LJCJQEJUSA-N
InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/9349062

Cisatracurium is a cis-cis isomer of atracurium and five time as potent as atracurium. The drug is approved by FDA and marketed under the name Nimbex. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation due to its antagonistic properties toward nicotinic acetylcholine receptors.

Originator

Sources: ISBN-13: 978-1461484400
Curator's Comment:: Now part of GlaxoSmithKline.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
54.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NIMBEX

Approved Use

Cisatracurium besylate injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.

Launch Date

8.1898563E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22 min
0.1 mg/kg 1 times / day steady-state, intravenous
dose: 0.1 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
CISATRACURIUM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Severe anaphylactic reaction to cisatracurium.
1999 Feb
[Precurarization of succinylcholine with cisatracurium: the influence of the precurarization interval].
2002 Sep
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
2006 Sep
Cisatracurium in "weakening doses" assists in weaning from sedation and withdrawal following extended use of inhaled isoflurane.
2007 Jan
Patents

Sample Use Guides

The recommended initial doses is 0.2 mg/kg, however it should be individualized. A dose of 0.03 mg/kg is recommended for maintenance of neuromuscular block during prolonged surgical procedures.
Route of Administration: Intravenous
Human umbilical vein endothelial cells were incubated with 0, 0.96, 3.2, 9.6, 32, and 96 microM of cisatracurium for 72 h and the drug (3.2 microM) decreased the cell count to 50% (SD, 8.6%).
Name Type Language
CISATRACURIUM
VANDF   WHO-DD  
Common Name English
CISATRACURIUM ION
Common Name English
(1R,2R,1'R,2'R)-2,2'-(PENTANE-1,5-DIYLBIS(OXY(3-OXOPROPANE-3,1-DIYL)))BIS(1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-2-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINIUM)
Common Name English
CISATRACURIUM [WHO-DD]
Common Name English
CISATRACURIUM CATION
Common Name English
ISOQUINOLINIUM, 2,2'-(1,5-PENTANEDIYLBIS(OXY(3-OXO-3,1-PROPANEDIYL)))BIS(1-((3,4-DIMETHOXYPHENYL)METHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-, (1R,2R,1'R,2'R)-
Common Name English
CISATRACURIUM [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175720
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
WHO-ATC M03AC11
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
NDF-RT N0000175732
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
WHO-VATC QM03AC11
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
NCI_THESAURUS C66886
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
Code System Code Type Description
LACTMED
Cisatracurium
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
EVMPD
SUB01319MIG
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
NCI_THESAURUS
C77365
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
DRUG CENTRAL
661
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
FDA UNII
QX62KLI41N
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
CAS
96946-41-7
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
MESH
C101584
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
DRUG BANK
DB00565
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
RXCUI
319864
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
Cisatracurium
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY
PUBCHEM
62887
Created by admin on Fri Jun 25 23:07:17 UTC 2021 , Edited by admin on Fri Jun 25 23:07:17 UTC 2021
PRIMARY